Lecado

Quick links to important sections

Lecado

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lecado

Defining Lecado: A Fixed-Dose Combination Agent

Property Description
Active ingredient Levodopa and Carbidopa
Form Tablet, Modified-release capsule/tablet, Enteral suspension
Pharmacological class Dopaminergic agent / Central Nervous System agent
Common use Replacement therapy for motor symptoms
Origin Synthetic (Chemically synthesized)

Lecado is a prescription-only medication defined as a fixed-dose combination product containing two essential, chemically synthesized compounds: levodopa and carbidopa, which is often referred to by the generic name co-careldopa. This combination is classified pharmacologically as a dopaminergic agent and a central nervous system agent. This structure is clinically recognized as the definitive therapeutic class for managing movement issues related to the lack of a crucial brain chemical. Popular brands containing this same combination include Sinemet and Rytary, differentiating Lecado through its specific formulation choices, which may include variations in tablet coating or release mechanism.


Composition, Forms, and General Purpose

Lecado's core composition involves the active ingredients levodopa and carbidopa, two agents required to effectively restore a critical chemical balance in the brain. Levodopa functions as a dopamine precursor or prodrug; it is the building block that crosses the blood-brain barrier to be converted into the necessary chemical messenger. The second component, carbidopa, is a peripheral decarboxylase inhibitor whose purpose is to shield the levodopa from premature breakdown outside the brain, ensuring the maximum possible amount reaches its target. This combination strategy is key to reducing the amount of levodopa needed and minimizing peripheral effects. This combined medication is available in various pharmaceutical preparations for oral and enteral administration, including standard tablets, modified-release tablets (also called prolonged-release forms), and extended-release capsules. The overall purpose is to provide replacement therapy that assists in improving control over body movements, managing stiffness, and reducing tremors, offering support in a typical use scenario where patients seek to maintain better motor function throughout the day.

What side effects are possible with Lecado?

Adverse Reaction Scope and Classification

The official regulatory safety profile for Lecado (levodopa/carbidopa) classifies adverse reactions across several physiological domains, including Nervous System, Psychiatric, Gastrointestinal, and Vascular disorders. The frequency of these effects is categorized according to established regulatory standards:

Classification Examples of Documented Reactions
Very Common (ge 1/10) Dyskinesia (involuntary movements), Urinary Tract Infection
Common (ge 1/100 to < 1/10) Hallucinations, Confusion, Dizziness, Nausea, Insomnia, Orthostatic Hypotension

Serious adverse reactions documented in regulatory sources include a Neuroleptic Malignant Syndrome-like symptom complex (associated with abrupt dose reduction or withdrawal) and the potential for Impulse Control Disorders (e.g., pathological gambling, hypersexuality).


Safety Constraints and Time-Related Patterns

The label specifies several high-level restrictions and constraints. Lecado is contraindicated in patients with narrow-angle glaucoma and in those with undiagnosed suspicious skin lesions or a history of melanoma. Caution is advised for patients with severe cardiac, pulmonary, renal, hepatic, or endocrine disease.

Time-related safety patterns are noted in official documents. Dyskinesia may appear at the onset of treatment, especially when converting from levodopa monotherapy. Conversely, the 'on-off' phenomenon (motor fluctuations) may appear months to years after the beginning of treatment and is often related to disease progression. Regarding special populations, safety and efficacy have not been established for pediatric use.


Regulatory Safety Summary

The full regulatory safety profile ensures all documented risks are presented with standardized frequency categories, defining the high-level boundaries and known safety characteristics associated with the medicine.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help

Overdose Scope

Feature Official Regulatory Statement
Documented overdose presentations Manifestations of excessive dopaminergic activity, including dyskinesia and blepharospasm, which is cited as a useful early sign of overdosage. Other presentations include CNS effects (confusion, hallucinations), and gastrointestinal effects (nausea, vomiting).
Physiological systems affected Central Nervous System (CNS), Cardiovascular System, and Musculoskeletal System (risk of Rhabdomyolysis and muscular rigidity).
Dose-related or exposure-related factors Manifestations are associated with overexposure requiring dosage reduction. Abrupt discontinuation or rapid dose reduction is linked to the life-threatening NMS-like syndrome.
Population-specific overdose notes Elderly patients may exhibit increased sensitivity to the CNS effects of the medication, such as confusion and hallucinations.
When immediate medical help is required Seek immediate medical attention for symptoms indicative of severe or life-threatening manifestations, specifically signs of the Neuroleptic Malignant Syndrome (NMS)-like symptom complex or severe cardiac arrhythmias.

Overdose Classifications (High-level)

Classification Official Regulatory Statement
Severity classification May lead to life-threatening outcomes, specifically the NMS-like symptom complex and severe cardiac arrhythmias.
Overdose-context constraints No specific antidote is documented; management relies on general supportive measures.

Official Overdose Statements

  • Severe outcomes include the NMS-like symptom complex (hyperpyrexia, rigidity) and cardiac arrhythmias.
  • For patients with a history of significant arrhythmias, cardiac function must be monitored in an intensive cardiac care facility.
  • Discontinuation should be tapered to mitigate the risk of the NMS-like syndrome.

Connection to the overall overdose profile

Regulatory documents define the Lecado overdose profile by detailing manifestations of excessive dopaminergic activity and specifying the severe outcomes, such as cardiac instability and NMS-like reactions. This risk profile mandates specific emergency actions, including seeking immediate medical attention for severe symptoms and requiring specialized hospital monitoring for patients with pre-existing cardiac risks. Management is limited to supportive care due to the lack of a documented specific antidote.

Therapeutic Uses of Lecado

Therapeutic Indications

Lecado is a combination medication primarily used to manage the motor symptoms associated with Parkinson’s disease and certain parkinsonian syndromes. It is specifically formulated to address the dopamine deficiency in the brain that characterizes these conditions.

Parkinson’s Disease

The primary application of Lecado is in the treatment of idiopathic Parkinson’s disease. In this condition, the loss of dopamine-producing neurons leads to significant motor impairments. Lecado helps alleviate the core symptoms of the disease, including:

  • Bradykinesia: The slowing of physical movement and the gradual loss of spontaneous activity.
  • Muscle Rigidity: Stiffness in the limbs and trunk, which can cause discomfort and limit range of motion.
  • Resting Tremor: Involuntary shaking that typically occurs when the muscles are at rest.
  • Postural Instability: Difficulties with balance and coordination that may increase the risk of falls.

Parkinsonian Syndromes

Beyond idiopathic Parkinson’s disease, Lecado may be used to treat symptoms in other parkinsonian syndromes. These include post-encephalitic parkinsonism and symptomatic parkinsonism which may follow carbon monoxide intoxication or manganese intoxication. By providing a source of dopamine that can reach the central nervous system, the medication helps improve functional mobility in these patients.

Mechanism of Action and Benefits

The effectiveness of Lecado stems from its dual-component approach to dopamine replacement therapy.

Symptom Management

By facilitating a more consistent level of dopamine in the brain, Lecado helps patients maintain better control over their movements. The primary benefit is the reduction of "off" periods—times when the medication wears off and symptoms return—and the enhancement of "on" periods, where mobility is improved.

Functional Improvement

Effective management of motor symptoms often leads to broader benefits for the patient’s quality of life. These include:

  • Improved ability to perform daily activities such as walking, dressing, and eating.
  • Reduction in the physical effort required to initiate movement.
  • Greater ease in maintaining posture and balance during transitions, such as rising from a chair.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Lecado?

The official regulatory profile for Lecado (co-careldopa) is defined by absolute exclusions and conditional requirements, establishing strict boundaries for who may use the medicine.

Eligibility Scope

  • Populations for whom use is allowed: Adult patients with Parkinson's disease and related symptomatic parkinsonism.
  • Populations for whom use is not recommended: The pediatric population (under 18 years), as safety and efficacy have not been established.
  • Populations for whom use is contraindicated: Patients with known hypersensitivity to the ingredients, narrow-angle glaucoma, a history of malignant melanoma, or severe psychoses. Use is also prohibited for patients taking nonselective monoamine oxidase (MAO) inhibitors.
  • Condition-specific eligibility rules: Caution is required for patients with severe renal, hepatic, pulmonary, or cardiovascular disease, as well as a history of peptic ulcer disease.
  • Pregnancy and lactation eligibility status: Use is generally not recommended or contraindicated during pregnancy, and women of childbearing potential should use effective contraception. Avoid breastfeeding while taking the medicine.

Resulting Eligibility Structure

Official regulatory documents establish mandatory exclusions and conditional use. The medicine is contraindicated in groups like patients with melanoma or narrow-angle glaucoma. The profile ensures use is limited to the approved adult population, while classifying use in children as not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented interaction patterns strictly based on regulatory prescribing information.

Contraindicated and Restricted Combinations

Co-administration with non-selective Monoamine Oxidase (MAO) Inhibitors is formally contraindicated due to the risk of severe hypertensive reactions; these agents must be discontinued at least two weeks before starting Lecado. The use of Dopamine-Depleting Agents is not recommended as they may reduce the therapeutic effect. Selective MAO Type B inhibitors may be administered only at the manufacturer’s recommended dose.

Pharmacokinetic and Exposure-Altering Interactions

Substances can alter the systemic exposure of levodopa. Iron Salts (e.g., ferrous sulfate) significantly decrease the bioavailability of both levodopa and carbidopa, requiring dose separation. Conversely, COMT Inhibitors and Metoclopramide are documented to potentially increase levodopa exposure. The absorption of levodopa may also be impaired by a high protein diet due to documented competition for intestinal transport.

Pharmacodynamic Effects and Timing Constraints

Antihypertensive Agents may result in symptomatic postural hypotension when co-administered. Dopamine D2 Receptor Antagonists can reduce the therapeutic effects of Lecado. Furthermore, a mandatory separation window of at least twelve hours is required when switching a patient from levodopa monotherapy to Lecado.

Mechanism of Action

Lecado is a monoclonal antibody that targets the pro-inflammatory cytokine interleukin-17A (IL-17A). The antibody binds specifically and with high affinity to the circulating IL-17A molecule, leading to the neutralization of the cytokine's biological activity.

This molecular interaction prevents free IL-17A from engaging with its cell-surface receptor (IL-17RA/RC) located on various cell types, including keratinocytes, fibroblasts, and epithelial cells. The blockade of receptor binding interrupts the subsequent intracellular signaling cascade.

Downstream of the receptor, this interruption inhibits key processes, including the activation of the transcription factor NF-mathbfkappa​B and the resulting gene expression that controls the release of various chemokines and mediators (e.g., IL-6 and IL-8). The net effect is a modification of local inflammatory processes and a reduction in the concentration of pro-inflammatory cellular components within tissues.

Dosage and Administration Information

Lecado (co-careldopa) is administered via two primary official routes: oral for various tablet and capsule forms, and enteral for the suspension, which requires specialized jejunal infusion. The core dosing principle centers on achieving a minimum daily carbidopa intake, typically 70 mg to 100 mg, which is necessary to ensure the levodopa component is adequately protected from premature breakdown outside the central nervous system.

The starting regimen for a levodopa-naïve patient often begins with one 25 mg/100 mg tablet three times a day. The dose is then titrated slowly based on the patient’s individual needs, with adjustments permitted no more frequently than every one to three days. The required frequency, which can range from three to five times daily, is highly variable, and the maximum levodopa dose depends on the specific formulation being used.

Administration rules are strictly form-specific. Extended-Release tablets must be swallowed whole and must not be crushed, chewed, or divided. The contents of specific extended-release capsules, however, may be sprinkled onto applesauce and taken immediately. Oral forms may be taken with or without food, but official labels caution that high-protein or high-fat meals can delay or reduce the absorption of the levodopa component. The enteral suspension requires a precise, continuous 16-hour daily infusion period, preceded by bringing the cassette to room temperature. Therapy should be gradually tapered if discontinuation is planned; abrupt cessation is discouraged. Use is not recommended for pediatric patients as safety is not established for those under 18 years.

Recent Clinical Evidence

Lecado is a modified-release tablet containing a combination of levodopa and carbidopa, which are used in the management of Parkinson’s disease symptoms.

Phase 3 Clinical Trials

Research has explored whether the combination of Compound A and Compound B (Lecado) is associated with study findings in patients with Condition X (Parkinson’s disease). Trials focused on individuals experiencing chronic, moderate-to-severe motor fluctuations refractory to first-line agents.

  • Primary Findings: The primary outcome measure was a change in the pain intensity score as measured on the Visual Analog Scale (VAS) at week 12. Studies evaluated whether the use of Lecado was associated with findings regarding the required dosage of rescue medications.
  • Biological Activities: Research explored underlying biological activities associated with the components of Lecado.
  • Long-Term Exposure: Research has investigated the association between the drug and study outcomes related to motor function scores, as well as long-term exposure in clinical settings. The studies examined outcomes reported over a 52-week period.

Subgroup and Safety Data

Research examined whether the formulation was associated with patient adherence in the study population.

  • Dosing Outcomes: Studies explored outcomes associated with different prescribed dose levels for individuals with severe chronic pain related to Parkinson's disease.
  • Onset Findings: Phase 3 trials reported data regarding the time until participants experienced initial effects. The trials did not assess comparative effectiveness against older treatments.
  • Study Safety Data: The studies documented adverse events among participants, including a potentially higher incidence of dyskinesia compared to the immediate-release formulation in patients with advanced motor fluctuations. The trials excluded participants with severe liver impairment from the study population.

Limitations of Current Evidence

Evidence remains limited regarding use in the pediatric population; the current body of research focuses only on adults over 18 years of age. It is not yet clear whether outcomes observed in the Phase 3 population translate to all individuals with the condition.

Key Studies & References

  1. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease
  2. Parkinson's disease in adults: diagnosis and management (NICE Guideline NG71)

Frequently Asked Questions (FAQ)

Common questions about Lecado (FAQ)

Q: Is Lecado a steroid or a blood thinner?

A: Official regulatory classification defines Lecado (co-careldopa) as a dopaminergic agent and a central nervous system agent. These classifications describe how the drug affects the central nervous system and its chemical messengers. This medicine is not classified as a steroid or a blood thinner.

Q: How quickly does Lecado usually start working?

A: Studies and official information indicate that data has been reported regarding the time until participants experienced initial effects in clinical trials. The time it takes to notice these initial effects can vary based on the specific formulation used and the individual patient.

Q: What are the most common side effects people report when starting Lecado?

A: According to the official product information, dyskinesia (involuntary movements) is classified as a Very Common adverse reaction (ge 1/10). This particular effect is noted in the safety summary as one that may appear shortly after the onset of treatment.

Q: Does taking Lecado cause weight gain or loss?

A: Official regulatory summaries have documented anorexia (loss of appetite) as a possible adverse effect. This effect is often noted particularly in the early stages of treatment.

Q: Is it normal to feel tired when you first start taking Lecado?

A: Common adverse events documented in the label include insomnia (trouble sleeping) and dizziness. Other effects on the central nervous system, such as drowsiness, are also documented in official sources.

Q: Are there any specific vitamins or supplements that should not be taken with Lecado?

A: Regulatory documents state that Iron Salts (such as ferrous sulfate supplements) are documented to decrease the bioavailability (absorption) of the active drug components. Official product information also notes the potential for the drug to cause low levels of Vitamin B6.

Q: Does Lecado interact with caffeine or alcohol?

A: Official information documents that alcohol may increase central nervous system side effects, such as dizziness and drowsiness. These warnings are based on how the body processes the medication.

Q: Is Lecado safe for people with kidney problems?

A: Regulatory documents advise that caution is required for patients who have severe renal disease (severe kidney problems). This is a conditional rule noted in the eligibility summary.

Q: Can elderly patients use Lecado safely?

A: Official documents note that the dosage should be reduced in older patients. The documentation also advises caution because mental disorders are reported as being more frequent in this population.

Q: What is the risk of an allergic reaction to Lecado?

A: The medicine is contraindicated, meaning it should not be used, in patients with known hypersensitivity (allergic reaction) to any of its ingredients. This is a mandatory exclusion stated in the regulatory profile.

Q: Is Lecado considered a long-term medication?

A: The medicine is generally intended to be taken every day for as long as prescribed. It is used in the management of symptoms of the condition and is not considered a cure.

Q: Does Lecado require special monitoring or blood tests?

A: The safety profile documents the potential for serious effects classified as Impulse Control Disorders, which often necessitate close monitoring. It also indicates the drug may affect specific laboratory results, such as urine sugar tests and Vitamin B6 levels.

Q: Can people with liver disease take Lecado?

A: Regulatory documents advise that caution is required for patients who have severe hepatic disease (severe liver problems). Furthermore, participants with severe liver impairment were excluded from clinical trials.

Q: Does taking Lecado affect the effectiveness of birth control?

A: Regulatory documents note that women of childbearing potential should use effective contraception during treatment. However, official information states that it is not known if this medication specifically affects the effectiveness of birth control methods.

Q: What does the FDA label say about taking Lecado with certain antidepressants?

A: Co-administration with non-selective Monoamine Oxidase (MAO) Inhibitors is formally contraindicated (prohibited) due to the risk of severe reactions. Selective MAO Type B inhibitors, which are another class of medicine, may be administered only at the manufacturer’s recommended dose.

Q: What is the general patient experience like when starting Lecado?

A: Official documents report study data on the frequency of various adverse events in participants. The label specifically notes that dyskinesia (involuntary movements) may appear at the onset of treatment.

Q: Do you have to take Lecado at the same time every day?

A: The official guidelines recommend taking the medicine at about the same time each day for the most consistent therapeutic effect. Official administration guidelines indicate patients should take the medicine this way.

Q: What is the difference between Lecado and a placebo in clinical trials?

A: Clinical trials formally investigate the difference in outcomes, such as changes in motor function scores, between the group using Lecado and the control group using a placebo (an inactive substance). This comparison is essential for establishing the drug's intended actions.

Q: Why is Lecado not suitable for people with a history of heart conditions?

A: Official documents advise caution for patients with severe cardiovascular disease (severe heart conditions). This is partly because co-administering the drug with blood pressure medications (antihypertensive agents) may result in symptomatic postural hypotension (a drop in blood pressure upon standing).

Q: Does Lecado affect driving ability?

A: Official warnings indicate that the medication may affect a person's coordination, reaction time, or judgment. Therefore, caution is advised regarding driving or operating heavy machinery.

Q: Can I take other prescription drugs with Lecado?

A: Co-administration with non-selective MAO Inhibitors is formally contraindicated (prohibited). The use of Dopamine-Depleting Agents is not recommended, and other specific interaction patterns are formally documented in the label.

Q: Are there any known issues with taking Lecado before surgery?

A: Regulatory information addresses the use during required general anesthesia. The label states that the medicine may be continued as long as the patient is permitted to take fluids and oral medication.

Q: What is the 'on-off' phenomenon?

A: Regulatory documents describe that the 'on-off' phenomenon refers to fluctuations in motor control. This can appear months to years after the beginning of treatment and is often related to the progression of the underlying condition.

Q: Is Lecado considered a Schedule drug or controlled substance?

A: Regulatory classification documents do not list the active ingredients (levodopa/carbidopa) as a Schedule I, II, III, IV, or V controlled substance under current regulations.

How should Lecado be stored and disposed of?

How to Store and Dispose of Lecado

Storage conditions for Lecado (levodopa/carbidopa) differ based on the pharmaceutical form and must adhere strictly to regulatory requirements.


Storage Requirements

Form Temperature Requirement Handling Constraint
Oral (Tablets/Capsules) Controlled Room Temperature (20 C to 25 C) Must be kept in a tightly closed container and protected from moisture; do not refrigerate or freeze.
Enteral Suspension Refrigerated (2 C to 8 C) for unopened cassettes Must not be frozen. Unopened cassettes are stable for only 15 days if stored at room temperature (up to 25 C).

All forms of Lecado must be stored out of the sight and reach of children.

Disposal

Unused or expired Lecado should be disposed of using an authorized drug take-back program or by following specific household trash guidelines (mixing with an undesirable substance in a sealed container). The product must not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lecado found in:

A-Z Index: